Referencias bibliográficas del articulo sobre el Síndrome ASIA.

Las siguientes son las referencias del artículo titulado:

Síndrome Autoinmune / Inflamatorio inducido por Adyuvantes (ASIA) 2013: Revelación de los aspectos patogénicos, clínicos y de diagnóstico.

Autores: Perricone C, Colafrancesco S, Mazor RD, Soriano A, Agmon – Levin N, Shoenfeld Y.

Publicado en: Journal of Autoimmunity. 2013 Diciembre; Volumen 47: páginas 1-16; 13 de noviembre del 2013.

Resumen

En 2011 un nuevo síndrome denominado «ASIA Síndrome Autoinmune / Inflamatorio inducido por Adyuvantes » se definió y justificó por primera vez resumir el espectro de enfermedades inmunes desencadenadas por un estímulo adyuvante tal como la exposición crónica a la silicona, tetrametilpentadecano, pristano, aluminio y otros adyuvantes, así como componentes microbianos, que también pueden tener un efecto adyuvante. Todos estos factores ambientales se han encontrado que inducen autoinmunidad por ellos mismos tanto en modelos animales como en seres humanos: por ejemplo, la silicona se asoció con siliconosis, el hidróxido de aluminio con fenómenos post-vacunación y síndrome miofascitis macrofágica. Se han planteado varios mecanismos hipotéticos como involucrados en la autoinmunidad inducida por adyuvante; una carga genética favorable juega un papel clave en la aparición de enfermedades relacionadas con las vacunas y que también explica la rareza de estos fenómenos. Este artículo se concentrará en los aspectos primordiales de hacen parte del Síndrome ASIA, enfocándose en las mecanismos de acción de los diferentes adyuvantes, que conducen a la respuesta inflamatoria o autoinmune. Los datos de este documento ilustran el papel crítico de factores medioambientales en la inducción de autoinmunidad. De hecho, es la interacción de la susceptibilidad genética y el ambiente los que protagonizan el inicio de esta ruptura de la tolerancia inmunológica.

http://www.ncbi.nlm.nih.gov/pubmed/24238833

BIBLIOGRAFIA

[1] Y. Shoenfeld, N. Agmon-Levin ASIA–Autoimmune/inflammatory syndrome induced by adjuvants J Autoimmun, 36 (2011), pp. 4–8

[2] Y. Shoenfeld Autoimmune (autoinflammatory) syndrome induced by adjuvants provides a diagnostic framework for enigmatic conditions The Rheumatologist, 6 (2011), pp. 26–32

[3] J.F. Carvalho, S.M. Barros, J.C. Branci, J.E. Fonseca ASIA or Shoenfeld’s syndrome: highlighting different perspective for diffuse chronic pain Acta Rheumatol Port, 36 (2011), pp. 10–12

[4] P.L. Meroni Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome? J Autoimmun, 36 (2011), pp. 1–3

[5] G.R.V. Hughes Foreword Lupus, 21 (2012), p. 117

[6] Y. Shoenfeld, G.R.V. Huges, N. Agmon-Levin The spectrum of ASIA: ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants’ Lupus, 21 (2012), pp. 118–120

[7] H. Rosenblum, Y. Shoenfeld, H. Amital The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome Infect Dis Clin North Am, 25 (2011), pp. 851–863

[8] E. Israeli, N. Agmon-Levin, M. Blank, Y. Shoenfeld Adjuvants and autoimmunity, vol. 18 (2009), pp. 1217–1225

[9] P. Youinou, J.O. Pers, M.E. Gershwin, Y. Shoenfeld Geo-epidemiology and autoimmunity J Autoimmun, 34 (2010), pp. 163–167

[10] Y. Shapira, N. Agmon-Levin, Y. Shoenfeld Defining and analyzing geoepidemiology and human autoimmunity J Autoimmun, 34 (2010), pp. 168–177

[11] D.P. Bogdanos, D.S. Smyk, P. Invernizzi, E.I. Rigopoulou, M. Blank, S. Pouria, et al. Infectome: a platform to trace infectious triggers of autoimmunity Autoimmun Rev, 12 (2013), pp. 726–740

[12] E. Toubi ASIA-autoimmune syndromes induced by adjuvants: rare, but worth considering Isr Med Assoc J, 14 (2) (2012 Feb), pp. 121–124

[13] R. Cervera ‘ASIA’: a new systemic autoimmune syndrome? Lupus, 20 (2011), pp. 665–666

[14] O. Vera-Lastra, G. Medina, M. del Pilar Cruz-Dominguez, P. Ramirez, J.A. Gayosso-Rivera, H. Anduaga-Dominguez, et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld’s syndrome) Lupus, 21 (2012), pp. 128–135

[15] E. Israeli, N. Agmon-Levin, M. Blank, Y. Shoenfeld Adjuvants and autoimmunity Lupus, 18 (2009), pp. 1217–1225

[16] V. Hornung, F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, et al. Silica crystals and aluminium salts activate the NALP3 inflammasome through phagosomal destabilization Nat Immunol, 9 (2008), pp. 847–856

[17] O. Barzilai, M. Ram, Y. Shoenfeld Viral infection can induce the production of autantibodies Curr Opin Rheumatol, 19 (2007), pp. 636–643

[18] K. Murali-Krishna, J.D. Altman, M. Suresh, D.J.D. Sourdive, A.J. Zajac, J.D. Miller, et al. Counting antigen specific CD8 T cells: a revaluation of bystander activation during viral infection Immunity, 8 (1998), pp. 177–187

[19] P.V. Lehmanann, T. Forthuber, A. Miller, E.E. Sercaz Spreading of T cell autoimmunity to cryptic determinants of an antigen Nature, 358 (1992), pp. 155–157

[20] Y. Zafrir, N. Agmon-Levin, Z. Paz, T. Shilton, Y. Shoenfeld Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants’ (ASIA): analysis of 93 cases Lupus, 21 (2012), pp. 146–152

[21] http://www.invivogen.com. 2013.

[22] A.T. Glenny, C.G. Pope, H. Waddington, U. Wallace Immunological notes: XVII-XXIV J Pathol Bacteriol, 29 (1926), pp. 31–40

[23] H. Hogenesch Mechanism of immunopotentiation and safety of aluminum adjuvants Front Immunol, 3 (2012), p. 406

[24] H. HogenEsch Mechanisms of stimulation of the immune response by aluminum adjuvants Vaccine, 20 (2002, 31), pp. S34–S39

[25] T.L. Flach, G. Ng, A. Hari, M.D. Desrosiers, P. Zhang, S.M. Ward, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity Nat Med, 17 (2011), pp. 479–487

[26] B. Pulendran, R. Ahmed Immunological mechanisms of vaccination Nat Immunol, 12 (2011), pp. 509–517

[27] L. Tomljenovic, C.A. Shaw Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations Lupus, 21 (2012), pp. 223–230

[28] F. Martinon, A. Mayor, J. Tschopp The inflammasomes: guardians of the body Annu Rev Immunol, 27 (2009), pp. 229–265

[29] S.C. Eisenbarth, O.R. Colegio, W. O’Connor, F.S. Sutterwala, R.A. Flavell Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants Nature, 19 (2008), pp. 1122–1126

[30] H. Li, S.B. Willingham, J.P. Ting, F. Re Cutting edge: inflammasome activation by alum and alum’s adjuvant effect are mediated by NLRP3 J Immunol, 181 (2008), pp. 17–21

[31] V. Hornung, F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, K.L. Rock, et al. Silica crystals and aluminum salts mediate NALP-3 inflammasome activation via phagosomal destabilization Nat Immunol, 9 (2008), pp. 847–856

[32] N.S. Al-Akl, M. Chakhtoura, N.F. Kazzi, J. Usta, C.A. Chamoun, A.M. Abdelnoor Uric acid: a possible mediator of the adjuvant effect of alum in mice immunized with ovalbumin World J Vaccines, 1 (2011), pp. 148–155

[33] M. Kool, T. Soullié, M. van Nimwegen, M.A. Willart, F. Muskens, S. Jung, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells J Exp Med, 205 (2008, 14), pp. 869–882

[34] M. Ulanova, A. Tarkowski, M. Hahn-Zoric, L.A. Hanson The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism Infect Immun, 69 (2001), pp. 1151–1159

[35] T. Marichal, K. Ohata, D. Bedoret, C. Mesnil, C. Sabatel, K. Kobiyama, et al. DNA released from dying host cells mediates aluminum adjuvant activity Nat Med, 17 (2011), pp. 996–1002

[36] A. Batista-Duharte, E.B. Lindblad, E. Oviedo-Orta Progress in understanding adjuvant immunotoxicity mechanisms Toxicol Lett, 203 (2011, 10), pp. 97–105

[37] E. Israeli, N. Agmon-Levin, M. Blank, J. Chapman, Y. Shoenfeld Guillain-Barré syndrome–a classical autoimmune disease triggered by infection or vaccination Clin Rev Allergy Immunol, 42 (2012), pp. 121–130

[38] I. Zivkovic, M. Stojanovic, V. Petrusic, A. Inic-Kanada, L. Dimitrijevic Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice Am J Reprod Immunol, 65 (2011), pp. 492–502

[39] D.P. Bogdanos, H. Smith, Y. Ma, H. Baum, G. Mieli-Vergani, D. Vergani A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics Clin Dev Immunol, 12 (2005), pp. 217–224

[40] M.S. Weber, M. Benkhoucha, K. Lehmann-Horn, D. Hertzenberg, J. Sellner, M.L. Santiago-Raber, et al. Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease PLoS One, 5 (2010, 30), p. e16009

[41] M. Kawahara, M. Kato-Negishi Link between aluminum and the pathogenesis of Alzheimer’s disease: the integration of the aluminum and amyloid cascade hypotheses Int J Alzheimers Dis, 2011 (2011), p. 276393

[42] C.R. Harrington, C.M. Wischik, F.K. McArthur, G.A. Taylor, J.A. Edwardson, J.M. Candy Alzheimer’s-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients Lancet, 343 (1994), pp. 993–997

[43] E. Miller, P. Waight, C.P. Farrington, N. Andrews, J. Stowe, B. Taylor Idiopathic thrombocytopenic purpura and MMR vaccine Arch Dis Child, 84 (2001), pp. 227–229

[44] E. Israeli Gulf War syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvants (ASIA) Lupus, 21 (2012), pp. 190–194

[45] D. Staines Do vasoactive neuropeptide autoimmune disorders explain pyridostigmine’s association with Gulf War syndrome? Med Hypotheses, 65 (2005), pp. 591–594

[46] K.E. Lucas, P.C. Rowe, H.K. Armenian Latency and exposure-health associations in Gulf War veterans with early fatigue onsets: a casecontrol study Ann Epidemiol, 17 (2007), pp. 799–806

[47] G.S. Gronseth Gulf war syndrome: a toxic exposure? A systematic review Neurol Clin, 23 (2005), pp. 523–540

[48] M.A. McDiarmid, S.M. Engelhardt, C.D. Dorsey, M. Oliver, P. Gucer, J.M. Gaitens, et al. Longitudinal health surveillance in a cohort of Gulf War veterans 18 years after first exposure to depleted uranium J Toxicol Environ Health A, 74 (2011), pp. 678–691

[49] H.V. Thomas, N.J. Stimpson, A.L. Weightman, F. Dunstan, G. Lewis Systematic review of multi-symptom conditions in Gulf War veterans Psychol Med, 36 (2006), pp. 735–747

[50] D.S. Ciccone, L. Weissman, B.H. Natelson Chronic fatigue syndrome in male Gulf war veterans and civilians: a further test of the single syndrome hypothesis J Health Psychol, 13 (2008), pp. 529–536

[51] K. Ismail, K. Kent, R. Sherwood, et al. Chronic fatigue syndrome and related disorders in UK veterans of the Gulf War 1990-1991: results from a two-phase cohort study Psychol Med, 38 (2008), pp. 953–961

[52] M.M. Amin, Z. Belisova, S. Hossain, M.S. Gold, J.E. Broderick, A.R. Gold Inspiratory airflow dynamics during sleep in veterans with Gulf War illness: a controlled study Sleep Breath, 15 (2010), pp. 333–339

[53] M. Hotopf, A. David, L. Hull, K. Ismail, C. Unwin, S. Wessely Role of vaccinations as risk factors for ill health in veterans of the Gulf War: cross sectional study BMJ, 320 (2000), pp. 1363–1367

[54] G.A.W. Rook, A. Zumla Gulf war syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile? Lancet, 349 (1997), pp. 1831–1833

[55] E.P. Grady, M.T. Carpenter, C.D. Koenig, S.A. Older, D.F. Battafarano Rheumatic findings in Gulf War veterans Arch Intern Med, 158 (1998), pp. 367–371

[56] C.R. Alving, G.M. Swartz Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity Crit Rev Immunol, 10 (1991), pp. 441–453

[57] C.R. Alving, N.M. Wassef, M. Potter Antibodies to cholesterol: biological implications of antibodies to lipids Curr Top Microbiol Immunol, 210 (1996), pp. 181–186

[58] R.K. Gherardi, F.J. Authier Macrophagic myofasciitis: characterization and pathophysiology Lupus, 21 (2012), pp. 184–189

[59] R.K. Gherardi, M. Coquet, P. Chérin, F.J. Authier, P. Laforêt, L. Bélec, et al. Macrophagic myofasciitis: an emerging entity. Groupe d’Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l’Association Française contre les Myopathies (AFM) Lancet, 352 (1998), pp. 347–352

[60] R.K. Gherardi, M. Coquet, P. Cherin, L. Belec, P. Moretto, P.A. Dreyfus, et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle Brain, 124 (2001), pp. 1821–1831

[61] Z. Khan, C. Combadière, F.J. Authier, V. Itier, F. Lux, C. Exley, et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain BMC Med, 11 (2013 Apr 4), p. 99

[62] R.K. Gherardi, F.J. Authier Aluminum inclusion macrophagic myofasciitis: a recently identified condition Immunol Allergy Clin North Am, 23 (2003), pp. 699–712

[63] P. Cherin, F.J. Authier, R.K. Gherardi, N. Romero, P. Laforêt, B. Eymard, et al. Gallium-67 scintigraphy in macrophagic myofasciitis Arthritis Rheum, 43 (2000), pp. 1520–1526

[64] M. Couette, M.F. Boisse, P. Maison, P. Brugieres, P. Cesaro, X. Chevalier, et al. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction J Inorg Biochem, 103 (2009), pp. 1571–1578

[65] F.J. Authier, S. Sauvat, J. Champey, I. Drogou, M. Coquet, R.K. Gherardi Chronic fatigue syndrome in patients with macrophagic myofasciitis Arthritis Rheum, 48 (2003), pp. 569–570

[66] C. Exley, L. Swarbrick, R.K. Gherardi, F.J. Authier A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome Med Hypothesis, 72 (2009), pp. 135–139

[67] F.J. Authier, P. Cherin, A. Creange, B. Bonnotte, X. Ferrer, A. Abdelmoumni, et al. Central nervous system disease in patients with macrophagic myofasciitis Brain, 124 (2001), pp. 974–983

[68] J.F. Carvalho, S.M. Barros, J.C. Branco Asia or Shoenfeld’s syndrome: highlighting different perspectives for diffuse chronic pain Acta Reumatol Port, 36 (2011), pp. 10–12

[69] W. Kaiser, G. Biesenbach, U. Stuby, P. Grafinger, J. Zazgornik Human adjuvant disease: remission of silicone induced autoimmune disease after explantation of breast augmentation Ann of the Rheum Disees, 49 (1990), pp. 937–938

[70] M. Caldeira, A.C. Ferreira Siliconosis: autoimmune/inflammatory syndrome induced by adjuvants (ASIA) Isr Med Assoc J, 14 (2) (2012 Feb), pp. 137–138

[71] J. McCarthy (Ed.), Aesthetic breast surgery, Saunders, Philadelphia (1990)

[72] L. Gylbert, O. Asplund, G. Jurell Capsular contracture after breast reconstruction with silicone-gel and saline-filled implants: a 6-year follow-up Plast Reconstr Surg, 85 (1990), pp. 73–377

[73] D.E. Barker, M.I. Retsky, S. Schultz ‘Bleeding’ of silicone from bagel breast implants, and its clinical relation to fibrous capsule reaction Plast Reconstr Surg, 61 (1978), pp. 836–841

[74] D. Flassbeck, B. Pfleiderer, P. Klemens, K.G. Heumann, E. Eltze, A.V. Hirner Determination of siloxanes, silicon, and platinum in tissues of women with silicone gel-filled implants Anal Bioanal Chem, 375 (2003), pp. 356–362

[75] L. Sagi, S. Baum, A. Lyakhovitsky, A. Barzilai, D. Shpiro, H. Trau, et al. Silicone breast implant rupture presenting as bilateral leg nodules Clin Exp Dermatol, 34 (2009), pp. e99–101

[76] C.J. Schaefer, P.H. Wooley The influence of silicone implantation on murine lupus in MRL lpr/lpr mice J Rheumatol, 26 (1999), pp. 2215–2221

[77] C.J. Schaefer The influence of silicone implantation on experimental models of autoimmunity EDT Collection for Wayne State University (January 1, 1997)

[78] D. Wolfram, E. Rabensteiner, C. Grundtman, G. Böck, C. Mayerl, W. Parson, et al. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis Plast Reconstr Surg, 129 (2012), pp. 327e–337e

[79] R.M. Goldblum, R.P. Pelley, A.A. O’Donell, D. Pyron, J.P. Heggers Antibodies to silicone elastomers and reactions to ventriculoperitoneal shunts Lancet, 340 (1992), pp. 510–513

[80] E. Bar-Meir, S.S. Teuber, H.C. Lin, I. Alosacie, G. Goddard, J. Terybery, et al. Multiple auto-antibodies in patients with silicone breast implants J Autoimmun, 8 (1995), pp. 267–277

[81] G. Zandman-Goddard, M. Blank, M. Ehrenfeld, B. Gilburd, J. Peter, Y. Shoenfeld A comparison of auto-antibody production in asymptomatic and symptomatic women with silicone breast implants J Rheumatol, 26 (1999), pp. 73–77

[82] N. Agmon-Levin, Y. Shoenfeld Chronic fatigue syndrome with auto-antibodies – the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant Autoimmun Rev, 8 (2008), pp. 52–55

[83] B.O. Shoaib, B.M. Patten Human adjuvant disease: presentation as a 414 multiple sclerosis-like syndrome South Med J, 89 (1996), pp. 179–188

[84] M. Lidar, N. Agmon-Levin, P. Langevitz, Y. Shoenfeld Silicone and scleroderma revisited Lupus, 21 (2012), pp. 121–127

[85] S.A. Van Nunen, P.A. Gatenby, A. Basten Post-mammoplasty connective tissue disease Arthritis Rheum, 25 (1982), pp. 694–697

[86] Y. Levy, P. Rotman-Pikielny, M. Ehrenfeld, Y. Shoenfeld Silicone breast implantation-induced scleroderma: description of four patients and a critical review of the literature Lupus, 18 (2009), pp. 1226–1232

[87] E. Bar-Meir, M. Eherenfeld, Y. Shoenfeld Silicone gel breast implants and connective tissue disease–a comprehensive review Autoimmunity, 36 (2003), pp. 193–197

[88] K.M.T. Miyoshi, Y. Kobayashi, T. Itakura, K. Nishijo Hypergammaglobulinemia by prolonged adjuvanticity in men. Disorders developed after augmentation mammoplasty Jpn Med J, 2122 (1964), pp. 9–14

[89] S. Kivity, M. Katz, P. Langevitz, I. Eshed, D. Olchovski, A. Barzilai Autoimmune syndrome induced by adjuvants (ASIA) in the Middle East: morphea following silicone implantation Lupus, 21 (2012), pp. 136–139

[90] A. Ueki, Y. Isozaki, A. Tomokuni, H. Ueki, M. Kusaka, S. Tanaka, et al. Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain Immunobiology, 204 (2001), pp. 458–465

[91] L.G. Meier, H.R. Barthel, C. Seidl Development of polyarthritis after insertion of silicone breast implants followed by remission after implant removal in 2 HLA-identical sisters bearing rheumatoid arthritis susceptibility genes J Rheumatol, 24 (1997), pp. 1838–1841

[92] E.W. Karlson, I.M. Lee, N.R. Cook, J.E. Buring, C.H. Hennekens, K.J. Bloch Serologic evaluations of women exposed to breast implants J Rheumatol, 28 (2001), pp. 1523–1530

[93] S.S. Teuber, M.J. Rowley, S.H. Yoshida, A.A. Ansari, M.E. Gershwin Anti-collagen autoantibodies are found in women with silicone breast implants J Autoimmun, 6 (1993), pp. 367–377

[94] D. Rahamim-Cohen, Y. Shoenfeld The mosaic of autoimmunity. A classical case of inhalation of a polyclonal activating factor in a genetically and hormonally susceptible patient leading to multiple autoimmune diseases Isr Med Assoc J, 3 (2001), pp. 381–382

[95] P.O. Fanger Hidden olfs in sick buildings ASHRAE, 30 (1988), pp. 40–43

[96] E. Israeli, A. Pardo The sick building syndrome as a part of the autoimmune (auto-inflammatory) syndrome induced by adjuvants Mod Rheumatol, 21 (2011), pp. 235–239

[97] D. Norback An update on sick building syndrome Curr Opin Allergy Clin Immunol, 9 (2009), pp. 55–59

[98] S. Brasche, M. Bullinger, M. Morfeld, H.J. Gebhardt, W. Bischof Why do women suffer from sick building syndrome more often than men? subjective higher sensitivity versus objective causes Indoor Air, 11 (2001), pp. 217–222

[99] S. Burge, A. Hedge, S. Wilson, J.H. Bass, A. Robertson Sick building syndrome: a study of 4373 office workers Ann Occup Hyg, 31 (1987), pp. 493–504

[100] E.J. Bardana Jr., A. Montanaro, M.T. O’Hollaren Building-related illness. A review of available scientific data Clin Rev Allergy, 6 (1988), pp. 61–89 [101] R.A. Ruhl, C.C. Chang, G.M. Halpern, M.E. Gershwin The sick building syndrome. II. Assessment and regulation of indoor air quality J Asthma, 30 (1993), pp. 297–308

[102] P.A. Steerenberg, C.E. Withagen, J.A. Dormans, W.J. van Dalen, H. van Loveren, F.R. Casee Adjuvant activity of various diesel exhaust and ambient particles in two allergic models J Toxicol Environ Health A, 66 (2003), pp. 1421–1439

[103] A.J. Barsky, J.F. Borus Functional somatic syndromes Ann Intern Med, 130 (1999), pp. 910–921

[104] Y.J. Tsai, M.E. Gershwin The sick building syndrome: what is it when it is? Compr Ther, 28 (2002), pp. 140–144

[105] A.W. Campbell, J.D. Thrasher, R.A. Madison, A. Vojdani, M.R. Gray, A. Johnson Neural autoantibodies and neurophysiologic abnormalities in patients exposed to molds in water-damaged buildings Arch Environ Health, 58 (2003), pp. 464–474

[106] F. Lander, H.W. Meyer, S. Norn Serum IgE specific to indoor moulds, measured by basophil histamine release, is associated with building-related symptoms in damp buildings Inflamm Res, 50 (2001), pp. 227–231

[107] M.R. Gray, J.D. Thrasher, R. Crago, R.A. Madison, L. Arnold, A.W. Campbell, et al. Mixed mold mycotoxicosis: immunological changes in humans following exposure in water-damaged buildings Arch Environ Health, 58 (2003), pp. 410–420

[108] A. Aron-Maor, Y. Shoenfeld Vaccination and systemic lupus erythematosus: the bidirectional dilemmas Lupus, 10 (2001), pp. 237–240

[109] S. van Assen, N. Agmon-Levin, O. Elkayam, R. Cervera, M.F. Doran, M. Dougados, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases Ann Rheum Dis, 70 (2011), pp. 414–422

[110] M. Bijl, N. Agmon-Levin, J.M. Dayer, E. Israeli, M. Gatto, Y. Shoenfeld Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment Autoimmun Rev, 11 (2012), pp. 572–576

[111] C. Perricone, N. Agmon-Levin, G. Valesini, Y. Shoenfeld Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego Jt Bone Spine, 79 (2012), pp. 1–3

[112] C. Thomas, M. Moridani Interindividual variations in the efficacy and toxicity of vaccines Toxicology, 278 (2010), pp. 204–210

[113] A.D. Cohen, Y. Shoenfeld Vaccine-induced autoimmunity J Autoimmun, 9 (1996), pp. 699–703

[114] M. Tishler, Y. Shoenfeld Vaccination may be associated with autoimmune diseases Isr Med Assoc J, 6 (2004), pp. 430–432

[115] R.P. Wise, K.P. Kiminyo, M.E. Salive Hair loss after routine immunizations J Am Med Assoc, 278 (1997), pp. 1176–1178

[116] V. Molina, Y. Shoenfeld Infection, vaccines and other environmental triggers of autoimmunity Autoimmunity, 38 (2005), pp. 235–245

[117] L. Tomljenovic, C.A. Shaw Aluminum vaccine adjuvants: are they safe? Curr Med Chem, 18 (2011), pp. 2630–2637

[118] C. Selmi, P.M. Battezzati, M.E. Gershwin, M. Tishler, Y. Shoenfeld Vaccines in the 21st century: the genetic response and the innocent bystander Autoimmun Rev, 4 (2005), pp. 79–81

[119] A.T. Borchers, C.L. Keen, Y. Shoenfeld, J. Silva Jr., M.E. Gershwin Vaccines, viruses, and voodoo J Investig Allergol Clin Immunol, 12 (2002), pp. 155–168

[120] N. Agmon-Levin, Z. Paz, E. Israeli, Y. Shoenfeld Vaccines and autoimmunity Nat Rev Rheumatol, 5 (2009), pp. 648–652 [121] H.A. Harima, N.F. Mendes, E.M. Mamizuka, M. Mariano Effect of glucan on murine lupus evolution and on host resistance to Klebsiella pneumoniae J Clin Lab Anal, 11 (1997), pp. 175–178

[122] W.H. Johnston, H. Latta Acute hematogenous pyelonephritis induced in the rabbit with Saccharomyces cerevisiae. An electron microscopic study Lab Invest, 29 (1973), pp. 495–505

[123] L. Luján, M. Pérez, E. Salazar, N. Álvarez, M. Gimeno, P. Pinczowski, et al. Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep Immunol Res, 56 (2013), pp. 317–324

[124] M. Satoh, W.H. Reeves Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane J Exp Med, 180 (1994), pp. 2341–2346

[125] M. Satoh, A. Kumar, Y.S. Kanwar, W.H. Reeves Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane Proc Natl Acad Sci U S A, 92 (1995), pp. 10934–10938

[126] M. Satoh, H.B. Richards, V.M. Shaheen, H. Yoshida, M. Shaw, J.O. Naim, et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane Clin Exp Immunol, 121 (2000), pp. 399–405

[127] Y. Kuroda, D.C. Nacionales, J. Akaogi, W.H. Reeves, M. Satoh Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine Biomed Pharmacother, 58 (2004), pp. 325–337

[128] P. Cruz-Tapias, N. Agmon-Levin, E. Israeli, J.M. Anaya, Y. Shoenfeld Autoimmune (Auto-inflammatory) syndrome induced by adjuvants (ASIA) – animal models as a proof of concept Curr Med Chem, 20 (2013), pp. 4030–4036

[129] T. Lasky, G.J. Terracciano, L. Magder, C.L. Koski, M. Ballesteros, D. Nash, et al. The Guillain-Barré syndrome and the 1992–1993 and 1993–1994 influenza vaccines N Engl J Med, 339 (1998), pp. 1797–1802

[130] P. De Wals, G. Deceuninck, E. Toth, N. Boulianne, D. Brunet, R.M. Boucher, et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec J Am Med Assoc, 308 (2012), pp. 175–181

[131] R. Baxter, N. Lewis, N. Bakshi, C. Vellozzi, N.P. Klein CISA Network. Recurrent Guillain-Barre syndrome following vaccination Clin Infect Dis, 54 (2012), pp. 800–804

[132] M. Khamaisi, Y. Shoenfeld, H. Orbach Guillain-Barré syndrome following hepatitis B vaccination Clin Exp Rheumatol, 22 (2004), pp. 767–770

[133] W. Huynh, D.J. Cordato, E. Kehdi, L.T. Masters, C. Dedousis Post-vaccination encephalomyelitis: literature review and illustrative case J Clin Neurosci, 15 (2008), pp. 1315–1322

[134] K. Maeda, R. Idehara Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccination Intern Med, 51 (2012), pp. 1931–1933

[135] Z. Mendoza Plasencia, M. González López, M.L. Fernández Sanfiel, J.R. Muñiz Montes Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus Neurologia, 25 (2010), pp. 58–59

[136] V. Schäffer, S. Wimmer, I. Rotaru, R. Topakian, H.P. Haring, F.T. Aichner HPV vaccine: a cornerstone of female health a possible cause of ADEM? J Neurol, 255 (2008), pp. 1818–1820

[137] I. Sutton, R. Lahoria, I. Tan, P. Clouston, M. Barnett CNS demyelination and quadrivalent HPV vaccination Mult Scler, 15 (2009), pp. 116–119

[138] N. Agmon-Levin, S. Kivity, M. Szyper-Kravitz, Y. Shoenfeld Transverse myelitis and vaccines: a multi-analysis Lupus, 18 (2009), pp. 1198–1204

[139] J.N. Ablin, Y. Shoenfeld, D. Buskila Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle J Autoimmun, 27 (2006), pp. 145–152

[140] S. Appel, J. Chapman, Y. Shoenfeld Infection and vaccination in chronic fatigue syndrome: myth or reality? Autoimmunity, 40 (2007), pp. 48–53 [141] Y. Shoenfeld Infections, vaccines and autoimmunity Lupus, 18 (2009), pp. 1127–1128

[142] B.A. Slade, L. Leidel, C. Vellozzi, E.J. Woo, W. Hua, A. Sutherland, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine J Am Med Assoc, 302 (2009), pp. 750–757

[143] C. Chao, N.P. Klein, C.M. Velicer, L.S. Sy, J.M. Slezak, H. Takhar, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine J Intern Med, 271 (2012), pp. 193–203

[144] Y. Shoenfeld HPV vaccines and autoimmune diseases J Intern Med, 272 (2012), p. 98

[145] C. Haug The risks and benefits of HPV vaccination J Am Med Assoc, 302 (2009), pp. 795–796

[146] C. Perricone, N. Agmon-Levin, Y. Shoenfeld Novel pebbles in the mosaic of autoimmunity BMC Med, 11 (2013), p. 101

[147] L. Tomljenovic, C.A. Shaw Death after quadrivalent human. Papillomavirus (HPV) vaccination: causal or coincidental? Pharmaceut Reg Affairs, S12 (2012), p. S001

[148] S.H. Lee Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil® vaccination—a case report Adv Biosci Biotechnol, 3 (2012), pp. 1214–1224

[149] J. Chang, D. Campagnolo, T.L. Vollmer, R. Bomprezzi Demyelinating disease and polyvalent human papilloma virus vaccination J Neurol Neurosurg Psychiatr, 82 (2011), pp. 1296–1298

[150] H.F. Soldevilla, S.F. Briones, S.V. Navarra SLE systemic lupus erythematosus following HPV immunization or infection? Lupus, 21 (2012), pp. 158–161

[151] M. Gatto, N. Agmon-Levin, A. Soriano, R. Manna, R. Maoz-Segal, S. Kivity, et al. Human papillomavirus vaccine and systemic lupus erythematosus Clin Rheumatol, 32 (2013), pp. 1301–1307

[152] D.T. Little, H.R. Ward Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination BMJ Case Rep, 2012 (2012)

[153] S. Colafrancesco, C. Perricone, L. Tomljenovic, Y. Shoenfeld Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants Am J Reprod Immunol, 70 (2013), pp. 309–316

[154] M.J. Thieben, P. Sandroni, D.M. Sletten, L.M. Benrud-Larson, R.D. Fealey, S. Vernino, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience Mayo Clin Proc, 82 (2007), pp. 308–313

[155] S. Blitshteyn Postural tachycardia syndrome after vaccination with Gardasil Eur J Neurol, 17 (2010), p. e52

[156] L. Tomljenovic, C.A. Shaw Too fast or not too fast: the FDA’s approval of Merck’s HPV vaccine Gardasil J Law Med Ethics, 40 (2012), pp. 673–681

[157] L. Tomljenovic, C.A. Shaw Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds? Ann Med, 45 (2013), pp. 182–193

[158] Y. Mikaeloff, G. Caridade, S. Suissa, M. Tardieu Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood Neurology, 72 (2009), pp. 873–880

[159] M.A. Hernán, S.S. Jick, M.J. Olek, H. Jick Recombinant hepatitis B vaccine and the risk of multiple sclerosis A prospective study Neurology, 63 (2004), pp. 838–842

[160] D. Konstantinou, C. Paschalis, T. Maraziotis, P. Dimopoulos, H. Bassaris, A. Skoutelis Two episodes of leukoencephalitis associated with recombinant Hepatitis B vaccination in a single patient Clin Infect Dis, 33 (2001), pp. 1772–1773 [161] N. Agmon-Levin, Y. Zafrir, Z. Paz, T. Shilton, G. Zandman-Goddard, Y. Shoenfeld Ten cases of systemic lupus erythematosus related to hepatitis B vaccine Lupus, 18 (2009), pp. 1192–1197

[162] J.F. Maillefert, C. Tavernier, J. Sibilia, E. Vignon Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano et al and the letter by Senécal et al Arthritis Rheum, 43 (2000), pp. 468–469

[163] D.F. Battafarano, N.J. Battafarano, L. Larsen, P.D. Dyer, S.A. Older, S. Muehlbauer, et al. Antigen-specific antibody responses in lupus patients following immunization Arthritis Rheum, 41 (1998), pp. 1828–1834

[164] J.-L. Senécal, C. Bertrand, F. Coutlée Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano et al (letter) Arthritis Rheum, 42 (1999), pp. 1307–1308

[165] Y. Berkun, D. Mimouni, Y. Shoenfeld Pemphigus following hepatitis B vaccination–coincidence or causality? Autoimmunity, 38 (2005), pp. 117–119

[166] V. Bruzzese, A. Zullo, C. Hassan Connective tissue disease following epatitis B vaccination J Clin Rheumatol, 19 (2013), pp. 280–281

[167] C. Perricone, Y. Shoenfeld Hepatitis B vaccination and undifferentiated connective tissue disease: another brick in the wall of the autoimmune/inflammatory syndrome induced by adjuvants (Asia) J Clin Rheumatol, 19 (2013), pp. 231–233

[168] A. Altman, M. Szyper-Kravitz, Y. Shoenfeld HBV vaccine and dermatomyositis: is there an association? Rheumatol Int, 28 (2008), pp. 609–612

[169] J.F. de Carvalho, R.M. Pereira, Y. Shoenfeld Systemic polyarteritis nodosa following hepatitis B vaccination Eur J Intern Med, 19 (2008), pp. 575–578

[170] J.F. de Carvalho, Y. Shoenfeld Status epilepticus and lymphocytic pneumonitis following hepatitis B vaccination Eur J Intern Med, 19 (2008), pp. 383–385

[171] F. Conti, S. Rezai, G. Valesini Vaccination and autoimmune rheumatic diseases Autoimmun Rev, 8 (2008), pp. 124–128

[172] E.S. Vista, S.R. Crowe, L.F. Thompson, G.M. Air, J.M. Robertson, J.M. Guthridge, et al. Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus Lupus, 21 (2012), pp. 168–174

[173] N. Agmon-Levin, S. Kivity, Y. Shoenfeld Influenza vaccine and autoimmunity Isr Med Assoc J, 11 (2009), pp. 183–185

[174] A. Soriano, E. Verrecchia, A. Marinaro, M. Giovinale, C. Fonnesu, R. Landolfi, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature Lupus, 21 (2012), pp. 153–157

[175] H. Nohynek, J. Jokinen, M. Partinen, O. Vaarala, T. Kirjavainen, J. Sundman, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland PLoS One, 7 (2012), p. e33536

[176] S.E. Håberg, L. Trogstad, N. Gunnes, A.J. Wilcox, H.K. Gjessing, S.O. Samuelsen, et al. Risk of fetal death after pandemic influenza virus infection or vaccination N Engl J Med, 368 (2013), pp. 333–340

[177] A. Soriano, R. Manna Quantifying the efficacy of influenza vaccines Lancet Infect Dis, 12 (2012), pp. 659–660 author reply 660–1

[178] Y. Shoenfeld, A. Aron-Maor, A. Tanai, M. Ehrenfeld BCG and autoimmunity: another two-edged sword J Autoimmun, 16 (2001), pp. 235–240

[179] M. Tishler, Y. Shoenfeld BCG immunotherapy–from pathophysiology to clinical practice Expert Opin Drug Saf, 5 (2006), pp. 225–229

[180] C. Hofmann, M.O. Baur, H. Schroten Anti-NMDA receptor encephalitis after TdaP-IPV booster vaccination: cause or coincidence? J Neurol, 258 (2011), pp. 500–501 [181] S. Jariwala, N. Vernon, J. Shliozberg Henoch-Schönlein purpura after hepatitis A vaccination Ann Allergy Asthma Immunol, 107 (2011), pp. 180–181

[182] S.J. Park, J.I. Shin Henoch-Schönlein purpura after hepatitis a vaccination: the role of interleukin 10? Ann Allergy Asthma Immunol, 107 (2011), p. 550

[183] D. Schmöeller, M.W. Keiserman, H.L. Staub, F.P. Velho, M.F. Grohe Yellow fever vaccination and Kawasaki disease Pediatr Infect Dis J, 28 (2009), pp. 1037–1038

[184] E. Quiroz-Rothe, P.J. Ginel, J. Pérez, R. Lucena, J.L.L. Rivero Vaccine-associated acute polyneuropathy resembling Guillain-Barré syndrome in a dog Eur J Companion Anim Pract, 15 (2) (2005)

[185] H.J. Gerth Polymyalgia rheumatica and influenza vaccination Dtsch Med Wochenschr, 117 (1992), pp. 1259–1260

[186] D. Saadoun, P. Cacoub, D. Mahoux, A. Sbai, J.C. Piette Postvaccine vasculitis: a report of three cases Rev Med Interne, 22 (2001), pp. 172–176

[187] I. Damjanov, J.A. Amato Progression of renal disease in Henoch-Schonlein purpura after influenza vaccination J Am Med Assoc, 242 (1979), pp. 2555–2556

[188] F. De Keyser, J.M. Naeyaert, P. Hindryckx, D. Elewaut, P. Verplancke, I. Peene, et al. Immune-mediated pathology following hepatitis B vaccination. Two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption Clin Exp Rheumatol, 18 (2000), pp. 81–85

[189] A. Zaas, P. Scheel, A. Venbrux, D.B. Hellmann Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases J Rheumatol, 28 (2001), pp. 1116–1120

[190] B. Spaetgens, P. van Paassen, J.W. Tervaert Influenza vaccination in ANCA-associated vasculitis Nephrol Dial Transplant, 24 (2009), p. 3258

[191] R. Birck, I. Kaelsch, P. Schnuelle, L.F. Flores-Suárez, R. Nowack ANCA-associated vasculitis following influenza vaccination: causal association or mere coincidence? J Clin Rheumatol, 15 (2009), pp. 289–291

[192] M. Abu-Shakra, J. Press, S. Sukenik, D. Buskila Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies Clin Rheumatol, 21 (2002), pp. 369–372

[193] K. Perdan-Pirkmajer, G.G. Thallinger, N. Snoj, S. Čučnik, P. Žigon, T. Kveder, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease Lupus, 21 (2012), pp. 175–183

[194] G.S. Goldman, N.Z. Miller Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990–2010 Hum Exp Toxicol, 31 (2012), pp. 1012–1021

[195] P. Aaby, H. Whittle, C. Stabell Benn Why vaccine programmes can no longer ignore non-specific effects BMJ, 344 (2012), p. e3769

[196] L. Tomljenovic, Y. Shoenfeld Association between vaccination and Guillain-Barré syndrome Lancte Infect Dis, 13 (2013), pp. 730–731

[197] A. Kesselheim Safety, supply and suits –; ligation and the vaccine industry N Engl J Med, 364 (2011), pp. 1485–1487

[198] G.J. Nabel Designing tomorrow’s vaccines N Engl J Med, 368 (2013), pp. 551–560

[199] D.S. Diekema Improving childhood vaccination rates N Engl J Med, 366 (2012), pp. 391–393

[200] Y. Zafrir, N. Agmon-Levin, Y. Shoenfeld Post-influenza vaccination vasculitides: a possible new entity J Clin Rheumatol, 15 (2009), pp. 269–270 [201] H. Orbach, Y. Shoenfeld Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland Autoimmun Rev, 6 (2007), pp. 261–266

[202] S. Hajdu, N. Agmon-Levin, Y. Shoenfeld Silicone and autoimmunity Eur J Clin Invest, 41 (2011), pp. 203–211

[203] C. Selmi, Q. Lu, M.C. Humble Heritability versus the role of the environment in autoimmunity J Autoimmun, 39 (2012), pp. 249–252

[204] P.S. Leung, J. Wang, P. Naiyanetr, T.P. Kenny, K.S. Lam, M.J. Kurth, et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA J Autoimmun, 41 (2013), pp. 79–86

[205] E. Tiniakou, K.H. Costenbader, M.A. Kriegel Sex-specific environmental influences on the development of autoimmune diseases Clin Immunol, 149 (2013), pp. 182–191

[206] A.M. Rose, L.C. Bell Epistasis and immunity: the role of genetic interactions in autoimmune diseases Immunology, 137 (2012), pp. 131–138

[207] D.P. Bogdanos, D.S. Smyk, E.I. Rigopoulou, M.G. Mytilinaiou, M.A. Heneghan, C. Selmi, et al. Twin studies in autoimmune disease: genetics, gender and environment J Autoimmun, 38 (2012), pp. J156–J169

[208] M.C. Boissier, L. Semerano, S. Challal, N. Saidenberg-Kermanac’h, G. Falgarone Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction J Autoimmun, 39 (2012), pp. 222–228

[209] M. Gatto, M. Zen, A. Ghirardello, S. Bettio, N. Bassi, L. Iaccarino, et al. Emerging and critical issues in the pathogenesis of lupus Autoimmun Rev, 12 (2013), pp. 523–536

[210] Y. Shoenfeld The future of autoimmunity Clin Rev Allergy Immunol, 42 (2012), pp. 113–120

[211] C. Chighizola, P.L. Meroni The role of environmental estrogens and autoimmunity Autoimmun Rev, 11 (2012), pp. A493–A501

[212] F.M. Strickland, A. Hewagama, Q. Lu, A. Wu, R. Hinderer, R. Webb, et al. Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus J Autoimmun, 38 (2012), pp. J135–J143

[213] K.M. Pollard Gender differences in autoimmunity associated with exposure to environmental factors J Autoimmun, 38 (2012), pp. J177–J186

[214] A. Hasham, Y. Tomer Genetic and epigenetic mechanisms in thyroid autoimmunity Immunol Res, 54 (2012), pp. 204–213

[215] W.E. Barbeau What is the key environmental trigger in type 1 diabetes–is it viruses, or wheat gluten, or both? Autoimmun Rev, 12 (2012), pp. 295–299

[216] D. Germolec, D.H. Kono, J.C. Pfau, K.M. Pollard Animal models used to examine the role of the environment in the development of autoimmune disease: findings from an NIEHS expert panel workshop J Autoimmun, 39 (2012), pp. 285–293

[217] C. Selmi, P.S. Leung, D.H. Sherr, M. Diaz, J.F. Nyland, M. Monestier, et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop J Autoimmun, 39 (2012), pp. 272–284

[218] R. Uibo, Z. Tian, M.E. Gershwin Celiac disease: a model disease for gene-environment interaction Cell Mol Immunol, 8 (2011), pp. 93–95

[219] G.A. Rook Hygiene and other early childhood influences on the subsequent function of the immune system Dig Dis, 29 (2011), pp. 144–153

[220] F.W. Miller, L. Alfredsson, K.H. Costenbader, D.L. Kamen, L.M. Nelson, J.M. Norris, et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop J Autoimmun, 39 (2012), pp. 259–271 [221] E.W. Karlson, K. Deane Environmental and gene-environment interactions and risk of rheumatoid arthritis Rheum Dis Clin North Am, 38 (2012), pp. 405–426

[222] K.H. Costenbader, S. Gay, M.E. Alarcon-Riquelme, L. Iaccarino, A. Doria Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev, 11 (2012), pp. 604–609

[223] G.J. Tobon, J.O. Pers, C.A. Canas, A. Rojas-Villarraga, P. Youinou, J.M. Anaya Are autoimmune diseases predictable? Autoimmun Rev, 11 (2012), pp. 259–266

[224] Y. Zhang, D. Gao, K. Kluetzman, A. Mendoza, V.J. Bolivar, A. Reilly, et al. The maternal autoimmune environment affects the social behavior of offspring J Neuroimmunol, 258 (2013), pp. 51–60

[225] D. Luckey, D. Bastakoty, A.K. Mangalam Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice J Autoimmun, 37 (2011), pp. 122–128

[226] S.M. Fu, U.S. Deshmukh, F. Gaskin Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR J Autoimmun, 37 (2011), pp. 104–112

Corresponding author. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 52621, Israel. Tel.: +972 3 530 8070; fax: +972 3 535 2855.

Anuncios

9 thoughts on “Referencias bibliográficas del articulo sobre el Síndrome ASIA.

Deja un comentario - Leave a comment

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión / Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión / Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión / Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión / Cambiar )

Conectando a %s